Business
Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its full year and fourth quarter 2025 financial results on Friday, March 13, 2026 at 8:00 am ET before the U.S. financial markets open.
About this update from Acurx Pharmaceuticals, Inc.
[{"type":"text","content":"STATEN ISLAND, N.Y., Feb. 16, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its full year and fourth quarter 2025 financial results on Friday, March 13, 2026 at 8:00 am ET before the U.S. financial markets open.","length":450,"tagName":"p"},{"type":"text","content":"David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:","length":193,"tagName":"p"},{"type":"text","content":"Date: Friday, March 13, 2026","length":28,"tagName":"p"},{"type":"text","content":"Time: 8:00 a.m. ET","length":18,"tagName":"p"},{"type":"text","content":"Toll free (U.S.): 877-790-1503 Access ID: 13758852","length":50,"tagName":"p"},{"type":"text","content":"Click here for participant International Toll-Free access numbers","length":65,"tagName":"p"},{"type":"text","content":"About IbezapolstatIbezapolstat is the Company's lead antibiotic candidate preparing for international Phase 3 clinical trials to treat patients with C. difficile Infection (CDI). Ibezapolstat is a novel, orally administered antibiotic being developed as a Gram-Positive Selective Spectrum (GPSS®) antibacterial. It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections. Ibezapolstat's unique spectrum of activity, which includes C. difficile but spares other Firmicutes and the important Actinobacteria phyla, appears to contribute to the maintenance of a healthy gut microbiome. As previously announced, the Company has received final EMA and FDA advice for our ibezapolstat pivotal Phase 3 trials. Their advice included and confirmed the non-inferiority study design elements, the patient population, primary and secondary endpoints, and size of the registration safety database. Acurx also now has a clear international roadmap for conduct of its Phase 3 program and, if successful, requirements for US NDA submission and EU Marketing Authorization.","length":1191,"tagName":"p"},{"type":"text...